## **Humber Area Prescribing Committee**

**Date / Time** 2<sup>nd</sup> August 2023 13:00-15:00

Venue MS Teams

Chair Dr Sergio Raise

Notes / Action Points Luke Storr – Senior Pharmacy Technician, HUTH

Quorate: Yes / No No – JM to send papers to Dr Pothina (items ratified after meeting)

Attendance Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR)

Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM)

Joanne Goode – Chief Pharmacist – HUTH (JG)

Prof A Morice, Professor of Respiratory Medicine HUTH- (AM)

Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB)

Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK)

Marian Opoku-Fofie - Deputy Chief Pharmacist - Humber Teaching NHS Foundation Trust (MOF)

Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC)

Simon Priestley- Chief Pharmacist, NLAG (SP)

Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber (MK)

Natasha Suffil-Lead Pharmacist CHCP (NS)

Dr Pratik Basu- GP- The Birches medical practice (PB)

Apologies Daniel Newsome- Principal Pharmacist RDTC (DN)

Dr Anupam Sinha- NEL GP Prescribing Lead (AS)

Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee

(CH)

Emma Baggaley, Assistant Director Medicines Management (Superintendent Pharmacist), CHCP (EB)

Luke Storr – Senior Pharmacy Technician, HUTH (LS)

| Agenda<br>Number | Item                        | Discussion   | Action  | Lead | Due Date |
|------------------|-----------------------------|--|---------|------|----------|
| 2023.08.01       | Apologies                   | Noted above  |         |      |          |
| 2023.08.02       | Declarations of interest    | None   |         |      |          |
| 2023.08.03       | Minutes of previous meeting | Accepted as true record  |         |      |          |
| 2023.08.04       | Action Tracker              | Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies) June 2023: In progress July 2023: In progress August 2023: JM to update document with info from HFT and CHCP. Ratification of guidelines and SCFs Add type 2 diabetes guidelines as recommendation for discussion at IMOC (action complete) NEW actions To feedback IMOC recommendation to clinicians To feedback to APC when meeting between all services occurred December update – going around internal governances in trusts (HUTH/NLAG/Y&SFT/HDH) March update – still awaiting outcome from relevant governances, JM to discuss with Matthew Heppel May update – sent to RS, to review how to do costing. June update- JM discussed with Matthew Heppel and most urgent issue to resolve is step 1 of NICE guidance. Proposed to send the North Yorkshire APC approved guidance as Humber guidance to July guideline group. Then can work on the more complex local commissioning of other agents. | Ongoing | JM   | 9/23     |

| July update: JM to bring the NY&Y document to July guideline group August update: ICB wide document in line with NICE approved. (on agenda for information)  |         |          |      |
|--|---------|----------|------|
| Action tracker HERPC – Hydroxychloroquine SCF JM to prepare hydroxychloroquine SCF   | Ongoing | JM       | 6/23 |
| Outstanding actions from NLAPC Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs) December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole Feb update- Modafinil live in NEL Riluzole live in NEL March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update May update: Riluzole updated, modafinil still waiting for NL,mycophenolate to review June update: Modafanil still waiting on NL, JM to review mycophenolate for July guideline group July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group August update: JM corrected typo and uploaded modafanil with correction. JM to review mycophenolate SCF for neurology for September guideline group | Ongoing | JM/RS    | 8/23 |
| Outstanding actions from HERPC Renal repatriation: December update – JM to meet with renal Dec update – JM offered dates of meeting but no correspondence March update – Updating business case. May update- to meet with NHSE   | Ongoing | JM       | 8/23 |
| August update – to meet with NHSE  Ratification of joint formulary  To upload chapter 13 on netformulary and remove HERPC chapter  March update – still ongoing  May update- still ongoing  June update – still ongoing  | Ongoing | JM/AK/LS | 7/23 |

| July update – JM to final check then document against netformulary then remove HERPC chapter August update – JM checked to remove HERPC chapter |                 |          |       |
|---|-----------------|----------|-------|
| Ratification of joint formulary To add chapter 1 to netformulary (and remove HERPC chapter when complete)                                       | Ongoing         | AK/LS/JM | 9/23  |
| Blueteq compliance Non-compliance to NICE guidance in acute trusts and  | Ongoing         | JM       | 9/23  |
| financial impact  | Crigoria        | OW       | 0/20  |
| June update: JM to submit ustekinumab report in   |                 |          |       |
| gastroenterology HUTH when approved  JM to present infliximab maintenance and initiation audits in  |                 |          |       |
| gastroenterology HUTH when completed and approved   |                 |          |       |
| July update: JM started infliximab maintenance data   |                 |          |       |
| collection and requesting data for adalimumab in gastroenterology homecare. Ustekinumab audit report not  |                 |          |       |
| ready yet.  |                 |          |       |
| July update: JM to update next time   |                 |          |       |
| August update: data collection for infliximab started,  | Ongoing         | JM       | 8/23  |
| ustekinumab report not yet ready  Ratification of guidelines and SCFs   |                 |          |       |
| Infliximab in ASUC – to add additional information and re-  |                 |          |       |
| present when updated  |                 |          |       |
| July update: JM to update for next meeting, AK provided info  |                 |          |       |
| requested August update: JM awaiting costing of ciclosporin levels in   |                 |          |       |
| HUTH  |                 |          |       |
| Traffic Light Status  | Action complete | LS/AK    | 8/23  |
| To update formulary and red list  |                 |          | 0.400 |
| RTDC updates To update formulary with TAs which were approved   | Action complete | JM/LS/AK | 8/23  |
| Correspondence received   | To add to       | LS       | 8/23  |
| To add lipid and inclisiran guidance to joint formulary   | guideline group |          |       |
| meeting/guideline group dependant on which thought  |                 |          |       |
| appropriate to discuss inclisiran classification <b>AOB – ondansetron</b>   | Ongoing         | AK       | 8/23  |
| Pathway to be referred to NLAG M&T and to appropriate   | Chigoling       | / U X    | 0/20  |
| meeting in Northern Lincolnshire places   |                 |          |       |
| August update – M&T not met   |                 |          |       |

|            |                                | AOB – semaglutide  JM to review what it says on formulary regarding semaglutide  TA for obesity and ensure if TA listed to state product not launched in UK  August update - to review update to same as York and  Scarborough formulary  | Ongoing                           | JM | 8/23 |
|------------|--------------------------------|---|-----------------------------------|----|------|
| 2023.08.05 | Outstanding actions from HERPC | To merge on HAPC tracker  Correspondence Received Rheumatology to prepare pathway with rituximab without MTX August update – JM to contact Dr Ogumbambi for timeline October update – Arranging meeting to discuss guidance and timeframe December update – Meeting booked February update – Documents sent to Dr Ogumbambi – March update – JM chased Dr Ogumbambi as received NLAG documents April update – JM to chase Dr Ogumbambi again May update – To discuss at HUTH D&TC and added to D&TC action tracker June update – Discussed at HUTH D&TC and added to D&TC action tracker July update – on D&T action tracker to discuss at next D&Tc with Dr Ogumbambi August update – D&TC not met. To discuss at September D&TC, and JM to contact Dr Ogumbambi to confirm place of rituximab without methotrexate  Hydroxychloroquine SCF JM to discuss ophthalmology checks with rheumatology New action: JM to add Harrogate pathway to agenda when published. New Action: JM to meet with business manager in ophthalmology to discuss drafting HUTH pathway and work towards commissioning. September 2022 update – HUTH D&T are escalating internally via their escalation process. To prepare SCG (action for HAPC) October 2022 – HUTH D&TC haven't had reply from their escalation process December 2022 – HUTH D&TC haven't had reply from their escalation process | Added to HUTH D&T agenda  Ongoing | JM | 9/22 |

|            | T   |   | 1  | 1     |       |
|------------|---|---|--|-------|-------|
|            |   | February 2023 – To check PE&CE minutes March 2023 – To discuss PE&CE response at next D&TC April 2023 – To discuss at next HUTH D&TC May 2023 – re-escalated from HUTH D&TC June 2023- JM going to PE&CE July 2023 – JM to update next time  • Prescribing guidelines – Dienogest pathway JM to confirm prescribing arrangements with specialist team October update: JM contacted Mrs Allen who is service lead, noted not stocked in HUTH pharmacy, thus stock arranged in pharmacy. No response from e-mail to consultant but specialist nurse responded. November update – JM to check formularies and EMIS dispensing system. December update – JM to chase consultant February update – JM met consultant and going to update pathway March update – JM to update pathway May update – JM not updated pathway yet June update – Pathway for July guideline group (dependant on agenda size) July update – Pathway for September guideline group | Ongoing  | JM    | 7/23  |
| 2023.08.06 | Traffic Light Status                                      | Avacopan- Proposed as RED   | Update   |       |       |
|            |   | Avatrombopag- Proposed as RED   | formulary/red list   | LS/AK | 9/23  |
| 2023.08.07 | Feedback from Integrated Medicines Optimisation Committee | Difference in RAG status for Ferric Maltol discussed. Shared care working group to be set up for area.  | Noted  |       |       |
| 2023.08.08 | Work plans  | <ul><li>a) Joint formulary alignment</li><li>b) Shared care frameworks</li><li>c) Guidelines</li></ul>  | Ongoing for information only   |       |       |
| 2023.08.09 | Ratification of guidelines and SCFs                       | a) ICB Continuous Blood Glucose Monitoring (for info only)  To update on formulary and add Dexcom1. b) Sick Day Guidance in T2DM  To discuss with comms team re printing. c) Oral Paracetamol d) Amiodarone SCF  This is currently with enhanced services/NPT in Hull and East Riding. The arrhythmia team sits within HUTH and currently have a small number of patients in NEL/NL; however some usage of amiodarone within NLAG. Minor amendments regarding ECGs in primary care.   | a) Noted, JM to link<br>to formulary<br>b) JM to contact<br>comms team<br>c) Approved<br>d) Approved<br>e) Noted, to update<br>links in joint<br>formulary | JM    | 10/23 |

|            |                                    | e) Type 2 diabetes (for info only)   |                           |          |      |
|------------|------------------------------------|--|---------------------------|----------|------|
| 2023.08.10 | Ratification of joint formulary    | Nil this month   |                           |          |      |
| 2023.08.11 | RTDC updates                       | June 23- to update formulary   | Update formulary/red list | JM/LS/AK | 9/23 |
| 2023.08.12 | Minutes from subcommittees         | <ul><li>a) Joint formulary subcommittee (Nil)</li><li>b) Guideline subcommittee (May 2023)</li></ul>           | Attached for info only    |          |      |
| 2023.08.13 | Additional minutes for information | a) HUTH D&TC (June 2023) b) HFT DTG (Nil) c) NLAG M&T (Nil) d) NYY APC (Nil)                                   | Attached for info only    |          |      |
| 2023.08.14 | Correspondence received            | APC antimicrobial request- any antimicrobial guidance or applications should be referred to the steering group |                           |          |      |
| 2023.08.15 | AOB                                | APC Newsletter Apr-June  |                           |          |      |
| 2023.08.16 | Date of next meeting               | 6 <sup>th</sup> September 13.00 – 15.00 Teams  |                           |          |      |